- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05672420
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
A Multicenter, Phase Ib/II Trial of the Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cells in Treatment-induced Myelosuppression in Patients With Hematologic Malignancies (USMYE Trial)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Qiubai Li, Professor
- Phone Number: (027) 85726387
- Email: qiubaili@hust.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Wuhan Union Hospital
-
Contact:
- Qiubai Li, Professor
- Phone Number: (027) 85726387
- Email: qiubaili@hust.edu.cn
-
Principal Investigator:
- Qiubai Li, Professor
-
Wuhan, Hubei, China, 430030
- Wuhan Tongji Hospital
-
Contact:
- Yicheng Zhang, Professor
- Email: yczhang@tjh.tjmu.edu.cn
-
Principal Investigator:
- Yicheng Zhang, Professor
-
Wuhan, Hubei, China, 430014
- Wuhan Central Hospital
-
Contact:
- Hongxiang Wang, Professor
- Email: whitely1972@sina.com
-
Principal Investigator:
- Hongxiang Wang, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 75 years old;
Either type of primary hematologic malignancies listed below:
- Acute myeloid leukemia (AML, AML subtype M3 excluded) or acute lymphoblastic leukemia (ALL) diagosed according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, either treatment naive participants who are going to receive first induction therapy, or participants who failed first induction therapy and are going to receive re-inducton therapy;
- AML or ALL participants who achieved remission and are going to receive consolidation therapy;
- Relapsed/refractory AML or ALL participants who are going to receive first re-induction therapy;
- Phase II trial will also include: participants with primary hematological maligancies who are going to receive autologous hematopoietic stem cell transplantation (allo-HSCT) whereas are poor mobilizers (CD34+cell count in peripheral blood was below 11-19/μL before collection, or the amount of CD34+ cells transfused was below 2×10^6/kg in allo-HSCT), and the participants' peripheral superficial veins have smooth blood flow which can meet the demand for intravenous drip;
- The participant or his/her legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent;
- Male or female;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (by the day anti-cancer therapy is initiated)
- Estimated survival of at least 3 months;
Adequate major organ function:
- Respiratory function: indoor oxygen saturation of at least 95%;
- Cardiac function: ejection fraction of left ventricular of at least 45%;
- Hepatic function: alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value;
- Renal function: Serum creatinine of at most 1.5 times/upper limit of normal value;
- Participants who do not receive any type of anti-cancer therapy within 2 weeks before enrollment (radiation therapy, chemotherapy and/or immune therapy, et al.), and treatment-associated toxicities induced by previous therapy has recovered to Grade 1 or below (except for low grade toxities such as alopecia).
Exclusion Criteria:
- Overt central nervous system manifestations of hematologic malignancies at diagnosis;
- Secondary hematological maligancies;
- Body mass index (BMI) of more than 30 kg/m^2;
- Myelosuppression induced by conditions other than anti-cancer therapy;
- Previous radiation therapy performed on sternum or pelvis;
- Specifically diagnosed and uncontrolled infection at enrollment (Uncontrolled is defined as exhibiting ongoing signs and symptoms of infection without improvement despite anti-infective agents) ;
- Uncontrolled active bleeding at enrollment;
- Severe underlying comorbidities affecting survival, including cachexia, severe malnutrition, etc;
- Estimated survival of at most 48 hours;
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;
- History of or current human immunodeficiency virus (HIV) infection;
- Continuous usage of immunosuppressants or received organ transplantation in the last 6 months;
- Participation in clinical trials of other drugs within 6 weeks before enrollment;
- Previous participation in clinical stem cell research;
- Receiving any agent concurrently with UC-MSCs infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc) ;
- Severe allergic constitution, or known or suspected allergy to the study drug and its components;
- Known contraindication to receiving hematopoietic growth factors, transfusion of blood components, anti-infective agents;
- Female participants who are pregnant or breast feeding;
Participants with fertility plan;
Note: For female participants, they should be surgical sterilized or post-menopausal, or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; For male participants, they should be surgical sterilized or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study;
- Participants suffering from mental illness;
- Presence of drug abuse/addiction;
- History of other malignancies other than hematological malignancies within 3 years;
- Participants without signed informed consent;
- Participants with poor compliance and are unable to complete the whole course of the study;
- Participants with circumstances that, in the opinion of the investigator, may increase the risk of the participants or interfere with conduct of the clinical trial and the judgment of results (excessive tension, sensitivity or cognitive impairment, etc) ;
- Participants with other circumstances that are ineligible for enrollment in this study, in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: umbilical cord derived mesenchymal stem cells (UC-MSCs)
In the Phase Ib study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia, UC-MSCs will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, frequency of infusion will be preset with 3 escalation levels: frequency 1, frequency 2, frequency 3, total course of treatment: 2 weeks; In the Phase II study, participants will be those with treatment-induced myelosuppression and acute myeloid leukemia/acute lymphoblastic leukemia/primary hematological maligancies who are going to receive hematopoietic stem cell transplantation, UC-MSCs will be preset according to the recommended phase II dose (RP2D) from the Phase Ib study, total course of treatment: 2 weeks.
|
umbilical cord derived mesenchymal stem cells, intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicities(DLT)
Time Frame: 4 days after the last UC-MSCs dose, up to 12 days
|
During the DLT observation period, the subject has an adverse event that is reasonably related to UC-MSCs infusion (possibly, likely or definitely related).
|
4 days after the last UC-MSCs dose, up to 12 days
|
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From the day that the last UC-MSCs dose is used to up to 21 days
|
To investigate the safety characteristics, percentages will be calculated and grade will be evaluated.
|
From the day that the last UC-MSCs dose is used to up to 21 days
|
Maximum tolerated dose (MTD)
Time Frame: From the day that the last UC-MSCs dose is used to up to 4 days
|
During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/3 in the dose group of at least 6 evaluble subjects of the study drug after the last UC-MSCs dose.
|
From the day that the last UC-MSCs dose is used to up to 4 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to absolute neutrophil count recovery
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, time will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Incidence of febrile neutropenia
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Duration of febrile neutropenia
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, the duration will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Incidence of severe thrombocytopenia
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Time to severe thrombocytopenia recovery
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, time will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Incidence of severe anemia
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Time to severe anemia recovery
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, time will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Incidence of infetion
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Duration of infetion
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, the duration will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Incidence of bleeding
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Duration of bleeding
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, the duration will be measured in days.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Application rate of blood transfusion
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Application rate of anti-infective agents
Time Frame: From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
To investigate the efficacy characteristics, percentages will be calculated.
|
From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
|
Time to achievement of complete remission
Time Frame: From enrollment to up to 28 days
|
To investigate the efficacy characteristics, time will be measured in days.
|
From enrollment to up to 28 days
|
Duration of complete remission
Time Frame: From enrollment to maximun up to 2 years
|
To investigate the safety characteristics, the duration will be measured in days or months.
|
From enrollment to maximun up to 2 years
|
Event free survival
Time Frame: From enrollment to maximun up to 2 years
|
From enrollment to the day of any event.
|
From enrollment to maximun up to 2 years
|
Overall survival
Time Frame: From enrollment to maximun up to 2 years
|
From enrollment to the day of death caused by any reason.
|
From enrollment to maximun up to 2 years
|
Incidence of infusion reactions in 2 years
Time Frame: 2 years since the last UC-MSCs infusion
|
To investigate the safety characteristics, percentages will be calculated.
|
2 years since the last UC-MSCs infusion
|
Incidence of secondary tumor in 2 years
Time Frame: 2 years since the last UC-MSCs infusion
|
To investigate the safety characteristics, percentages will be calculated.
|
2 years since the last UC-MSCs infusion
|
Cumulative incidence of relapse of primary disease in 2 years
Time Frame: 2 years since the last UC-MSCs infusion
|
To investigate the safety characteristics, percentages will be calculated.
|
2 years since the last UC-MSCs infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Qiubai Li, Professor, Wuhan Union Hospital, China
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UHCT22668
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
University of PittsburghWithdrawn
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, MeningococcalGermany, France
-
GlaxoSmithKlineCompletedInfections, MeningococcalGermany
-
GlaxoSmithKlineCompletedInfections, MeningococcalKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
-
University of ZurichUnknownEscherichia Coli InfectionsSwitzerland
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States
Clinical Trials on umbilical cord derived mesenchymal stem cells
-
Central South UniversityUnknown
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
TrustemFundación Universitaria de Ciencias de la Salud; Hospital de San Jose; Hospital...Unknown
-
PT. Prodia Stem Cell IndonesiaRecruiting
-
Beijing 302 HospitalWuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd., Hubei, ChinaNot yet recruitingDecompensated CirrhosisChina
-
Meridigen Biotech Co., Ltd.RecruitingBronchopulmonary DysplasiaTaiwan
-
Beijing 302 HospitalVCANBIO Cell & Gene Engineering Corporation, LtdRecruitingDecompensated CirrhosisChina
-
Shanghai East HospitalRecruitingLung Injury | Ischemic Heart Disease | Non-cardiac SurgeryChina
-
Translational BiosciencesWithdrawnOsteoarthritis of the KneePanama
-
Affiliated Hospital to Academy of Military Medical...Unknown